1955 related articles for article (PubMed ID: 12136223)
1. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials in metastatic breast cancer to bone: past--present--future.
Body JJ
Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
[TBL] [Abstract][Full Text] [Related]
3. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
Body JJ
Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
8. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
10. Aredia: the once-monthly infusion for the treatment of bone metastases.
Lipton A
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
[TBL] [Abstract][Full Text] [Related]
11. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
13. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Powles T; McCroskey E; Paterson A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
15. Toward new horizons: the future of bisphosphonate therapy.
Lipton A
Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
18. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
20. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
van Holten-Verzantvoort AT; Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]